Loading company…
Vesalius Therapeutics uses patient data, genetics, and AI to develop treatments for disease.
Founded in 2019 and based in Massachusetts, Vesalius Therapeutics combines human data, genetics, and genomic information with AI and machine learning to study disease and develop drugs. Its Diamond platform identifies clinical patterns and genetic circuits, then uses patient-derived cell models to screen drug candidates. In March 2022, it raised USD 75 million in venture funding led by Flagship Pioneering.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in